Year: 2022

The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-toleratedAllschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the treatment of patients with difficult-to-control hypertension. The NDA includes data from a comprehensive clinical and non-clinical development program. In the Phase 3 registration study, PRECISION, aprocitentan showed statistically significant and clinically meaningful reduction in blood pressure (BP) which was maintained for up to 48 weeks...

SIKA OPENS NEW PLANT IN SOUTHWESTERN CHINA Sika is opening a new plant for liquid membranes and mortar production in Chongqing, a city in southwestern China with 30 million inhabitants. By commissioning the new plant, Sika is expanding its position in this rapidly growing metropolitan area, which is set to become even more important as China is creating the Chengdu-Chongqing business district with almost 100 million inhabitants. The automotive, finance, and logistics sectors are well represented in the Chengdu-Chongqing region, and the construction industry benefits from these operations and companies’ efforts to achieve more sustainable production. With its new state-of-the-art plant in this region, Sika will be well-positioned to meet rising demand from the construction industry for high-quality, sustainable products, and will greatly...

A trial in advanced cervical cancer will be initiated in 4Q2023 with potential registrational intentDose-finding Phase 1/2a trial in 1st line patients with advanced head and neck squamous cell carcinoma to begin in 1H2023Evaluate and plan for expansion into HPV16-positive anal, penile, vaginal and vulvar cancerExpanding clinical program into PD-L1 negative tumors— Management will host a webcast today at 11 a.m. CET (in Norwegian) and 4 p.m. CET / 10 a.m. ET (in English) to discuss the development plan Company selected to present at the 41st Annual J.P. Morgan Healthcare Conference in January 2023 OSLO, Norway, Dec. 20, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced an expanded...

Vancouver, Canada, Dec. 19, 2022 (GLOBE NEWSWIRE) — Oroco Resource Corp. (TSX-V: OCO, OTC: ORRCF) (“Oroco” or “the Company”) announces that its shareholders have approved the Company’s amended 10% rolling stock option plan (the “Plan”) at its Annual General Meeting of Shareholders held on December 16, 2022 (the “Meeting”).   The Plan The maximum number of common shares which may be issued under the Plan is 10% of the Company’s issued and outstanding share capital at the date of grant. The Plan has a ‟rolling” limit, as the number of shares reserved for issuance pursuant to the grant of stock options will automatically increase as the Company’s issued and outstanding share capital increases.  The limit includes outstanding stock options previously granted.  The Plan is subject to annual approval of shareholders and the TSX Venture...

Philadelphia, PA, Dec. 19, 2022 (GLOBE NEWSWIRE) — FTAC Zeus Acquisition Corp. (NASDAQ:ZING) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced its decision to cancel its special meeting scheduled for Wednesday, December 21, 2022. The Company decided to cancel the meeting because the amount of redemption requests it received would have resulted in the trust account falling below $125 million.  The Company had previously announced that it did not anticipate proceeding with the meeting if the trust account would fall below the $125 million threshold.  The Company intends to continue in its purpose of consummating an initial business combination prior to its scheduled termination date in August 2023.   Forward-Looking Statements This press release includes...